| Continuously evolving management concepts for diabetic CKD and ESRD. | |
| | |
MedLine Citation:
|
PMID: 20210916 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
During the past 50 years, a global pandemic of kidney failure attributed to diabetes mellitus provoked continuously changing treatment strategies based in the belief that micro- and macrovascular complications of diabetes may be preventable. Both patient and physician have revised, and sometimes reversed drug regimens based on inferences extracted from prospective, controlled, properly populated trials. Illustrating this dilemma is a newly relaxed target for glycosylated hemoglobin (HbA1c) of 7%, introduced because of the greater rate of cardiovascular complications noted when striving to reduce attained HbA1c to < or = 6.5%. Our concept of the natural history of kidney disease in diabetes has repeatedly been modified by a rising mean age of those developing uremia (now 64.5 years). Underscoring the reality that the majority of diabetic kidney failure patients fall within the geriatric age group. An encouraging finding first reported in 2005 and continuing through 2009 is a declining incidence rate of irreversible advanced kidney failure in individuals known to have diabetes. That this "good news" results from appropriate renoprotective treatment is as yet unsubstantiated wishful thinking. |
| | |
Authors:
|
Eli A Friedman |
Related Documents
:
|
2073866 - Magnesium and insulin-dependent diabetes mellitus. 10509876 - Age and metabolic control influence lens opacity in type i, insulin-dependent diabetic ... 12874446 - Transcriptome profiling and the pathogenesis of diabetic complications. 16396516 - Thiazolidinediones : beyond glycemic control. 6360666 - Effect of dexamethasone on adipose tissue and liver pyruvate dehydrogenase and its stim... 17675466 - Altered b:9-23 insulin, when administered intranasally with cholera toxin adjuvant, sup... |
Publication Detail:
|
Type: Journal Article; Review Date: 2010-02-22 |
Journal Detail:
|
Title: Seminars in dialysis Volume: 23 ISSN: 1525-139X ISO Abbreviation: Semin Dial Publication Date: 2010 Mar-Apr |
Date Detail:
|
Created Date: 2010-06-07 Completed Date: 2010-09-28 Revised Date: 2010-11-10 |
Medline Journal Info:
|
Nlm Unique ID: 8911629 Medline TA: Semin Dial Country: United States |
Other Details:
|
Languages: eng Pagination: 134-9 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Nephrology Division, State University of New York, Downstate Medical Center, Brooklyn, NY, USA. eli.friedman@downstate.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin II Type 1 Receptor Blockers
/
therapeutic use Angiotensin-Converting Enzyme Inhibitors / therapeutic use Antihypertensive Agents / therapeutic use Antilipemic Agents / therapeutic use Diabetic Nephropathies / epidemiology, therapy* Hemoglobin A, Glycosylated / analysis Humans Hypoglycemic Agents / therapeutic use Kidney Failure, Chronic / epidemiology, therapy* Kidney Transplantation Pancreas Transplantation Peritoneal Dialysis Proteomics Uremia / etiology, prevention & control |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Antilipemic Agents; 0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Selection and Dosing of Medications for Management of Diabetes in Patients with Advanced Kidney Dise...
Next Document: Diabetic CKD/ESRD 2010: A Progress Report?